Repare Therapeutics (NASDAQ:RPTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a research report report published on Friday morning,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Separately, Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th.

Repare Therapeutics Price Performance

NASDAQ RPTX traded up $0.10 on Friday, reaching $3.59. The company had a trading volume of 70,883 shares, compared to its average volume of 162,200. The firm has a market capitalization of $152.40 million, a PE ratio of -2.19 and a beta of 0.72. The firm has a 50-day moving average of $3.35 and a 200-day moving average of $3.40. Repare Therapeutics has a 1 year low of $2.71 and a 1 year high of $8.49.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.03. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. As a group, sell-side analysts expect that Repare Therapeutics will post -2.15 EPS for the current fiscal year.

Institutional Trading of Repare Therapeutics

Several hedge funds have recently made changes to their positions in RPTX. Vontobel Holding Ltd. boosted its stake in Repare Therapeutics by 20.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares during the period. XTX Topco Ltd bought a new stake in shares of Repare Therapeutics in the 2nd quarter worth approximately $110,000. Exchange Traded Concepts LLC increased its holdings in shares of Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after buying an additional 8,809 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Repare Therapeutics during the second quarter worth $273,000. Finally, Opaleye Management Inc. acquired a new position in shares of Repare Therapeutics in the 1st quarter valued at $318,000. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.